Stockscreener 앱 받기
23.61
2.44%
-0.59
전일 마감가:
$24.20
열려 있는:
$24.08
하루 거래량:
1.54M
Relative Volume:
0.83
시가총액:
$3.98B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
131.17
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-6.53%
1개월 성능:
-7.23%
6개월 성능:
+40.79%
1년 성능:
+48.03%
1일 변동 폭
$23.34
$24.21
1주일 범위
$23.34
$25.90
52주 변동 폭
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.61 | 4.02B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
TD Cowen Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Acadia reports positive interim results from DAYBUE real-world study By Investing.com - Investing.com UK
90% Patient Improvement: Groundbreaking DAYBUE Drug Shows Long-term Success in Rare Rett Syndrome Study - Stock Titan
Baird Financial Group Inc. Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Comerica Bank Has $716,000 Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Acadia Pharmaceuticals stock price target raised to $39 by TD Cowen - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome - uk.finance.yahoo.com
UBS Group Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Sanofi wins big at the 2025 Fierce Pharma Marketing Awards - Fierce Pharma
Great Lakes Advisors LLC Acquires 72,667 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Scientech Research LLC Acquires 27,384 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Fed. Circ. Won't Revisit Double-Patenting, Soda TM Appeals - Law360
National Wealth Management Group LLC Makes New $328,000 Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Fred Alger Management LLC Increases Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Canada Pension Plan Investment Board Cuts Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Can ACADIA Pharmaceuticals Inc. generate free cash flowWeekly Stock Summary & Expert Approved Trade Ideas - Lancaster City Council
UBS Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $36, Maintains Buy Rating - MarketScreener
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2025 - BioSpace
Acadia Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceut - PharmiWeb.com
Anti-Parkinson's Drugs Global Markets to 2030 with AbbVie, Amneal Pharmaceuticals, Acadia Pharmaceuticals, Supernus Pharmaceuticals and Teva Pharmaceutical DominatingResearchAndMarkets.com - Business Wire
Graham Capital Management L.P. Grows Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Palo Alto Investors LP Has $44.25 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. stock daily chart insightsWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Key metrics from ACADIA Pharmaceuticals Inc.’s quarterly dataWeekly Trade Review & Daily Profit Maximizing Tips - Newser
Trexquant Investment LP Trims Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
What is ACADIA Pharmaceuticals Inc.’s valuation compared to sectorWeekly Volume Report & Precise Swing Trade Entry Alerts - خودرو بانک
Will earnings trigger a reversal in ACADIA Pharmaceuticals Inc.Earnings Summary Report & Free AI Powered Buy and Sell Recommendations - Newser
Can swing trading help recover from ACADIA Pharmaceuticals Inc. lossesTrade Analysis Summary & Short-Term High Return Strategies - Newser
Options Flow: Is ACADIA Pharmaceuticals Inc. a strong growth stock2025 Risk Factors & Accurate Technical Buy Alerts - خودرو بانک
Walleye Capital LLC Trims Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Is ACADIA Pharmaceuticals Inc. stock overvalued or fairly priced2025 Market WrapUp & Weekly Setup with ROI Potential - خودرو بانک
ACADIA Pharmaceuticals Inc. recovery potential after sell offPortfolio Value Report & AI Enhanced Trading Alerts - Newser
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Boosted by Point72 Europe London LLP - MarketBeat
Analyzing drawdowns of ACADIA Pharmaceuticals Inc. with statistical toolsJuly 2025 Sentiment & Fast Momentum Entry Tips - Newser
Signal strength of ACADIA Pharmaceuticals Inc. stock in tech scannersJuly 2025 Breakouts & Long-Term Safe Investment Ideas - Newser
Is ACADIA Pharmaceuticals Inc. forming a reversal patternEarnings Summary Report & Breakout Confirmation Alerts - Newser
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial - MSN
Should you avoid ACADIA Pharmaceuticals Inc. stock right now2025 Winners & Losers & Reliable Breakout Stock Forecasts - خودرو بانک
Pattern recognition hints at ACADIA Pharmaceuticals Inc. upsideJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Trend analysis for ACADIA Pharmaceuticals Inc. this weekQuarterly Profit Report & Free Technical Pattern Based Buy Signals - Newser
Kodai Capital Management LP Acquires Shares of 53,497 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Statistical indicators supporting ACADIA Pharmaceuticals Inc.’s strengthMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Using data models to predict ACADIA Pharmaceuticals Inc. stock movement2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - Newser
Sector ETF performance correlation with ACADIA Pharmaceuticals Inc.Bond Market & Real-Time Stock Movement Alerts - Newser
Director Sells Shares in ACADIA Pharmaceuticals - TipRanks
Acadia Pharmaceuticals director Garofalo sells $41,560 in stock - Investing.com
Acadia Pharmaceuticals director Garofalo sells $41,560 in stock By Investing.com - Investing.com UK
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):